A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia;Estudio comparativo entre inmunoglobulina intravenosa y plasmaféresis en el perioperatorio de la miastenia gravis

Revista de Neurologia

Volumn 33, Issue 5, 2001, Pages 413-416

  Pérez Nellar, Jesús ^a   Dominguez A M ^a   Llorens Figueroa, J A ^a   Ferra Betancourt A ^a   Pardo, A ^a   Quiala, M ^a   Gali, Z ^a  

^a HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

Immunoglobulin; Myasthenia gravis; Plasmapheresis

Indexed keywords

EID: 0345857997     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3305.2001132     Document Type: Article

References (47)

1. Gronseth GS, Barohn RB. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15.
2. Pérez-Nellar J, Negrín A, Llorens JA, Ferré A, Pardo A, Parisi N. Timectomía en la miastenia gravis: evolución a largo plazo y factores pronósticos. Rev Neurol 2000; 30: 801-6.
3. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial Analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychiatry 1991; 54: 406-11.
4. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymectomy in myasthenia gravis. Results of 662 cases operated upon in 15 years. Eur J Cardiothorac Surg 1989; 3: 504-9.
5. Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M, et al. Extended thymectomy for myasthenia gravis patients: a 20 years review. Ann Thorac Surg 1996; 62: 853-9.
6. Hatton PD, Diehl JT, Daly DT. Trans-sternal radical thymectomy for myasthenia gravis: a 15 years review. Ann Thorac Surg 1989; 47: 838-40.
7. Lindberg C, Andersen O, Larsson S, Oden A. Remision rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated. Acta Neurol Scand 1992; 86: 323-8.
8. Evoly H, Battochi AP, Provenzano C, et al. Thymectomy in the treatment of myasthenia gravis: reports of 247 patients. J Neurol 1998; 235: 272-6.
9. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al. Prognosis of myasthenia gravis: a multi-center follow-up study of 844 patients. J Neurol Sci 1991; 106: 213-20.
10. Mantegazza R, Beghi E, Pareison DA. Multicentre follow-up study of 1152 patients with myasthenia in Italy. J Neurol 1990; 137: 339-44.
11. Papatestas AE, Genkins G, Kornfield P. Effects of thymectomy in myasthenia gravis. Ann Surg 1987; 206: 79-88.
12. Urschel JD, Grewal RP. Thymectomy for myasthenia gravis. Postgrad Med 1998; 74: 139-44.
13. Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 2000; 4: 291-5.
14. Qureshi AI, Suri MF. Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience. Ther Apher 2000; 4: 280-6.
15. Batocchi AP, Evoli A, di Schino C, Tonali P. Therapeutic apheresis in myasthenia gravis. Ther Apher 2000; 4: 275-9.
16. Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453-62.
17. Seybold ME. Plasmapheresis in myastenia gravis. Ann N Y Acad Sci 1987; 505: 584-7.
18. Fatch-Moghadam A, Wick M, Besinger U. High dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 848-9.
19. Gajdos PH, Outin H, Elkharrat D. High dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 406-7.
20. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000; 23: 551-5.
21. Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol 2000; 22: 40-3.
22. Howard JF Jr. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998; 51 (Suppl 5): S30-6.
23. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999; 22: 1479-97.
24. Bril V, Allenby K, Midroni G, O'Connor PW, Vajsar J. IgIV in neurology-evidence and recommendations. Can J Neurol Sci 1999; 26: 139-52.
25. Jongen JL, van Doorn PA, van der Meché FGA. High-dose intravenous immunoglobulin therapy for myasthenia gravis. J Neurol 1998; 245: 26-31.
26. Arsura R. Experience with intravenous immunoglobulin in myastenia gravis. Clin Immunol Immunopathol 1989; 53 (Suppl 1): S70-9.
27. Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology 1997; 48 (Suppl 5): S64-9.
28. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myastenia gravis with high dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84: 81-4.
29. Gajdos PH, Cherret S, Clair B. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789-96.
30. Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52: 629-32.
31. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000; 23. 551-5.
32. Mahalati K, Dawson RB, Collins JO, Mayer RF. Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management. J Clin Apher 1999; 14: 1-8.
33. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999; 22: 1479-97.
34. Tatay J, Díez-Tejedor E, Frank A, Tejada J, Marrero C, Barreiro P. Asociación de plasmaféresis y dosis allas de inmunoglobulina intravenosa en el tratamiento de la miastenia gravis. Rev Neurol 1997; 25: 1402-6.
35. Naquib M, el-Dawalatly AA, Ashour M, Bamgboye EA. Multivariate determinants of the need for postoperative ventilation in myasthenia gravis. Can J Anaesth 1996; 43: 1006-13.
36. Gorback MS, Moon RE, Massey JM. Extubation after trans-sternal thymectomy for myasthenia gravis: a prospective analysis. South Med J 1991; 84: 701-6.
37. Eisenkraft JB, Papatestas AE, Kahn CH, Mora CT, Fagerstrom R, Genkis G. Predicting the need for postoperative mechanical ventilation in myasthenia gravis. Anaestesiology 1986; 65: 79-82.
38. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immunoglobulin treatment in neurologic disease. Neurology 1996; 47: 674-7.
39. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987; 82: 624-9.
40. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin (letter). Clin Nephrol 1992; 37: 216-7.
41. Ben-Chetrit E, Puttermann C. Transient neutropenia induced by intravenous immunoglobulin (letter). N Engl J Med 1991; 326: 270-1.
42. Majer RV, Green PJ. Neutropenia caused by intravenous immunoglobulin (letter). Br Med J 1988; 296: 1262.
43. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1649-11.
44. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994; 331: 1649-50.
45. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 259-62.
46. Nicholls MD, Cummings JC, Davies VJ, Grenwood JK. Haemolysis induced by intravenously administered immunoglobulin. Med J Aust 1989; 150: 404-6.
47. Dalakas MC. High-dose intravenous immunoglobuline and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.